Press releases

(August 23, 2004) -- Boston Scientific Corporation (NYSE: BSX) announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration to market its FilterWire EZ Embolic...

(August 19, 2004) -- Boston Scientific Corporation (NYSE: BSX) today announced that the U.S. Food and Drug Administration (FDA) has approved extending the shelf life of its TAXUS Express2...

(August 10, 2004) -- Boston Scientific Corporation (NYSE: BSX) today announced that it has made a significant equity investment in Northstar Neuroscience, Inc., a privately held company located in...

(August 5, 2004)

(July 26, 2004) -- Boston Scientific Corporation (NYSE: BSX) today announced financial results for its second quarter ended June 30, 2004. Net sales for the second quarter were $1.460 billion as...

(July 22, 2004) -- Boston Scientific Corporation (NYSE: BSX) today announced that it has received an Investigational Device Exemption from the U.S. Food and Drug Administration (FDA) to begin its...

(July 21, 2004) -- Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results for the second quarter ended June 30, 2004 on Monday, July 26, at 9:00...

(July 16, 2004) -- Boston Scientific Corporation (NYSE: BSX) announced today that it is expanding its voluntarily worldwide recall to include certain additional units of its TAXUS™ Express2™...

(July 8, 2004) -- Boston Scientific Corporation (NYSE: BSX) today announced that enrollment has begun in its clinical trial known as FLAME. This prospective, multi-center, randomized study will...

(July 2, 2004) -- Boston Scientific Corporation (NYSE: BSX) announced today that it is voluntarily recalling nationwide approximately 200 units of its TAXUS™ Express2™ Paclitaxel-Eluting...